Hillel Grossman, MD
Ask the Expert: Why have so many drugs that seem promising as treatments for Alzheimer’s failed when studied in actual patients?
These are the most important topics of research in Alzheimer’s. The answers to these questions hold the key to our ability to decipher the disease and find curative interventions. These are the questions that the Alzheimer’s Disease Neuroimaging Initiative (ADNI) was designed to answer.
Preliminary findings in Phase IIA trial point to natural compound NIC5-15′s potential in AD
Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer’s disease.
Synaptic proteins and phospholipid levels increase in rat pups whose mothers were given DHA plus uridine
Congratulations to George Marzloff, one of our ADRC research coordinators, who was recently published in the January 2009 issue of Developmental Neuroscience. While pursuing his undergraduate degree, George and other researchers from the Massachusetts Institute of Technology investigated the effects of supplementing rat mothers with uridine and docosahexaenoic acid (DHA) on the brains of rat [...]
Huperzine A Phase II Findings
“This US Phase II trial has clearly demonstrated efficacy of Huperzine A in the treatment of AD. Completion of the planned analyses, including examination of drug levels and cholinesterase inhibition, will be valuable in the design of further studies.”